Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already
AccesswireApr 22 09:00 ET
Express News | ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences
Moomoo 24/7Apr 12 09:03 ET
Express News | EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
Moomoo 24/7Mar 28 06:45 ET
Express News | EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
Moomoo 24/7Mar 28 06:45 ET
ImmunoPrecise Antibodies Acquires Carterra LSA Instrument
Seeking AlphaMar 20 07:36 ET
Express News | IPA Acquires The Carterra LSA Instrument to Enhance Antibody Discovery And Bolster Its AI Developments
Moomoo 24/7Mar 20 07:03 ET
Press Release: IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development an
Dow JonesMar 20 07:02 ET
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call Transcript
Yahoo FinanceMar 15 13:48 ET
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
Dow JonesMar 15 10:09 ET
Express News | HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
Moomoo 24/7Mar 15 09:24 ET
ImmunoPrecise Antibodies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 480.61% HC Wainwright & Co. → $9 Reiterates Buy → Buy 09/18/2023 480.61% HC Wainwright & Co. →
BenzingaMar 15 09:23 ET
Buy Rating Affirmed: ImmunoPrecise Antibodies' Growth and Innovation Drive Positive Outlook
TipRanksMar 15 06:15 ET
Earnings Call: IPA Sees 20% Revenue Rise Amid Strategic Expansions
ImmunoPrecise Antibodies (IPA) has reported a 20% increase in total revenue year-over-year for the third quarter of fiscal year 2024, despite a challenging macroeconomic climate.
Investing.com Mar 14 20:30 ET
Earnings Call Summary | ImmunoPrecise Antibodies(IPA.US) Q3 2024 Earnings Conference
The following is a summary of the ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript:Financial Performance:ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase
moomoo AIMar 14 16:50 ET · Conference Call
Express News | ImmunoPrecise Antibodies Q3 EPS $(0.11) Misses $(0.07) Estimate, Sales $6.22M Beat $4.50M Estimate
Moomoo 24/7Mar 14 08:17 ET
ImmunoPrecise GAAP EPS of -C$0.11, Revenue of C$6.2M
Seeking AlphaMar 14 08:09 ET
ImmunoPrecise Antibodies 3Q Research & Development Expenses $1M >IPA
ImmunoPrecise Antibodies 3Q Research & Development Expenses $1M >IPA
Dow JonesMar 14 08:06 ET
ImmunoPrecise Antibodies 3Q Loss/Shr 11c >IPA
ImmunoPrecise Antibodies 3Q Loss/Shr 11c >IPA
Dow JonesMar 14 08:06 ET
Press Release: IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue. VICTORIA, British Columbia--(BUSINESS
Dow JonesMar 14 08:05 ET
Earnings Outlook For ImmunoPrecise Antibodies
ImmunoPrecise Antibodies (NASDAQ:IPA) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement.Analysts estimate that Imm
BenzingaMar 13 15:02 ET
No Data
No Data